Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30⁺ lymphoproliferative disorder: A case report

Pediatr Blood Cancer. 2022 Jun;69(6):e29626. doi: 10.1002/pbc.29626. Epub 2022 Mar 24.

Authors

Giulia Ceglie^{1

2}, Rita De Vito³, Matilde Cossutta⁴, Alice Tiberi⁴, Roberto Carta¹, Emilia Boccieri¹, Giuseppe Palumbo^{1

4}

Affiliations

¹ Department of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
² Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
³ Department of Pathology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
⁴ University Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

PMID: 35322542
DOI: 10.1002/pbc.29626

No abstract available

Publication types

Case Reports

MeSH terms

Brentuximab Vedotin
Child
Humans
Immunoconjugates* / therapeutic use
Ki-1 Antigen
Lymphoproliferative Disorders* / drug therapy
Skin

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin